Efficacy of Ondansetron Suppository vs. Tablets for Chemotherapy-Induced Nausea
Author Information
Author(s): R de Wit, JH Beijnen, O van Tellingen, JHM Schellens, M de Boer-Dennert, J Verweij
Primary Institution: Rotterdam Cancer Institute
Hypothesis
Is a once-daily ondansetron suppository as effective as ondansetron tablets for preventing nausea and vomiting in chemotherapy patients?
Conclusion
The ondansetron suppository is effective in preventing nausea and vomiting associated with cyclophosphamide chemotherapy, despite lower plasma levels compared to the oral formulation.
Supporting Evidence
- The median AUC for the oral formulation was 226 ng ml-1h-1, while for the suppository it was 140 ng ml-1h-1.
- The median Cmax for the oral formulation was 50.5 ng ml-1, compared to 17.1 ng ml-1 for the suppository.
- Patients receiving the suppository had a median Tmax of 209 minutes, while those on tablets had a median Tmax of 60 minutes.
- Statistical analysis showed significant differences in pharmacokinetic parameters between the two formulations.
Takeaway
This study shows that a new type of medicine, ondansetron suppository, can help stop people from feeling sick after chemotherapy, even if it doesn't get into the body as much as the pill form.
Methodology
Patients were randomized to receive either a 16 mg ondansetron suppository once daily or 8 mg ondansetron tablets twice daily, and their nausea and vomiting were monitored.
Limitations
The small sample size limits the ability to draw definitive conclusions about the exposure-response relationship.
Participant Demographics
Median age was 47 years, with 17 females and 3 males participating.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website